ImmunityBio, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · San Diego, CA
IBRX chart
What traders are saying about $IBRX
Latest postsImmunityBio, Inc. news
- PepGen’s oligo succeeds in Phase 2; Ionis’ and ImmunityBio’s stocks sag
Endpoints News ·
- Can a 53% Anktiva Sales Rise Really Coexist With ImmunityBio (NASDAQ:IBRX) Falling About 20%?
kalkine.ca ·
- IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%
Yahoo Finance ·
- Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?
fool.com ·
- ImmunityBio, Inc. And Rafa Laboratories Ltd. Announce Israeli Ministry Of Health Approval Of ANKTIVA Plus BCG For BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ
www.marketscreener.com ·
- ImmunityBio shares slump 19% as revenue misses and going-concern warning hits sentiment
proactiveinvestors.com ·
- ImmunityBio Stock Tumbles 19% as Q3 Revenue Misses, Despite Bladder Cancer Trial Win
BigGo Finance ·
- Immunitybio Inc earnings missed by $0.10, revenue fell short of estimates
Investing.com ·
- Why Is ImmunityBio Stock Trading Lower On Monday? - ImmunityBio (NASDAQ:IBRX)
Benzinga ·
- $IBRX stock is down 25% today. Here's what we see in our data.
Quiver Quantitative ·
- ImmunityBio (IBRX) Stock Falls 18% Despite Cancer Trial Win and 92% Sales Growth
Blockonomi ·
- IBRX Stock Crashes To Near 9-Month Lows On Q3 Earnings Miss – Retail Says No Way To Escape Further Dilution
stocktwits.com ·
ImmunityBio, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622,000 | $240,000 |
| Net income | -$351.5M | -$413.6M | -$583.9M | -$417.3M |
| Diluted EPS | $-0.38 | $-0.62 | $-1.15 | $-1.04 |
| Total assets (year end) | $501.9M | $382.9M | $504.5M | $362.4M |
| Cash and equivalents (year end) | $88.3M | $143.4M | $265.5M | $104.6M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About ImmunityBio, Inc.
- Ticker
- IBRX (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Diego, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1326110
- Former names
- NantKwest, Inc., Conkwest, Inc., ZelleRx Corp
Frequently asked questions
What exchange is ImmunityBio, Inc. listed on?
ImmunityBio, Inc. trades on the Nasdaq under the ticker symbol IBRX.
What industry is ImmunityBio, Inc. in?
ImmunityBio, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is ImmunityBio, Inc. headquartered?
ImmunityBio, Inc.'s business address on file with the SEC is in San Diego, CA.
When does ImmunityBio, Inc.'s fiscal year end?
ImmunityBio, Inc.'s fiscal year ends on December 31.
How much revenue did ImmunityBio, Inc. report?
ImmunityBio, Inc. reported $113.3M in revenue for calendar year 2025, according to its SEC filings.